Verismo Therapeutics

Verismo is a pioneer in KIR-CAR technology. The KIR-CAR platform technology is developed specifically for solid tumors, an area of high unmet medical need.

[APR @AmPharmRev]

📰 #NEWS: Verismo Therapeutics and the Center for Vaccine and Cell Production Facility at the University of Pennsylvania Expand Partnership
https://t.co/MDbdrk3hAn

@VerismoTx @PennMedicine #Partnership #CVPF #ClinicalCellManufacturing

[Philadelphia Business Journal @PHLBizJournal]

Raymond Luke is the director of manufacturing science and technology and head of chemistry, manufacturing and controls at Verismo Therapeutics. Get to know more about the 40 Under Forty honoree. https://t.co/NGmpAb9e5A

[Verismo Therapeutics @VerismoTx]

FDA grants Verismo Therapeutics Fast Track designation for SynKIR-110, a potential new treatment for pleural mesothelioma, a rare and aggressive cancer. We look forward to advancing SynKIR-110 in our Phase 1 trial to reach patients sooner. #CART #Mesothelioma #VerismoTherapeutics

[Verismo Therapeutics @VerismoTx]

We're thrilled to announce that Verismo has secured $7M of pre-Series A financing to advance their KIR-CAR platform technology, designed to improve persistence and efficacy against aggressive solid tumors. #KIRCAR #VerismoTherapeutics
Full release: https://t.co/8ZK2GQaSbT

[Verismo Therapeutics @VerismoTx]

Tomorrow is @rarediseaseday! We at Verismo honor the millions of individuals & families affected by rare diseases & are committed to developing treatments that provide relief & hope. #ShareYourColors #LightUpForRare #RareDiseaseDay

[Verismo Therapeutics @VerismoTx]

Happy #CholangiocarcinomaAwarenessDay! We’re proud to join the fight against bile duct cancer and support those affected by this devastating disease. #Cholangiocarcinoma #CancerAwareness #FightCancer #SynKIR110 #WorldCCADay #PledgeforCCA

[CAR-TCR @CAR_TCell]

Verismo Therapeutics Expands Quality and Compliance Team: https://t.co/CSdHC0L3HK

#CARTCR #immunotherapy

[Verismo Therapeutics @VerismoTx]

We have been nominated for Breakthrough Company of the Year at the 3rd Annual BioBuzz Awards! Cast your vote for us today!

The deadline is 12/2 and for each vote a donation of $0.25 for STEM programming in South Baltimore communities.
#Cancer #STEM

https://t.co/uAg8ChrW1W

[AUTM @AUTM]

A @Penn #spinout @VerismoTx received @FDA approval for a drug study of a KIR-CAR T Cell #Immunotherapy to treat diseases with low survival rates and an urgent need for successful treatment options. #techtransfer

https://t.co/6awFq1lE5L

[Penn Innovation @PennPCI]

Congrats to @VerismoTx on their FDA Clearance of their Investigational New Drug application for SynKIR-110™, a KIR-CAR T cell immunotherapy candidate.

https://t.co/Gtnmk2S1Qs

[Verismo Therapeutics @VerismoTx]

This events supports pediatric cancer research @ChildrensPhila - a cause that closely matches our vision.

[Verismo Therapeutics @VerismoTx]

Today our team (#KIRRaceCARTs) ran in the #ParkwayRun. We are happy and honored to be able to participate and give back to such a worthy cause. Thank you to the organizers of the event, everyone that donated and, of course, the Verismo team!

[1stOncology @1stOncology]

#VerismoTherapeutics Announces #FDA Clearance of #IND Application for #SynKIR110 a #KIRCAR #TCell #Immunotherapy Candidate https://t.co/SjPLEEXOTN

[Precision Oncology News @PrecOncNews]

Verismo Therapeutics to Begin Phase I Trial of Autologous Cell Therapy SynKIR-110. Following the FDA's clearance of its IND, the UPenn spinout will start studying its cell therapy in patients with mesothelin-expressing ovarian cancer,... https://t.co/HsHnV9zJVh

[Verismo Therapeutics @VerismoTx]

This represents validation for the hard work from our team as well as hope our patients. #teamwork #celltherapy #CelliconValley #patientsfirst

[Verismo Therapeutics @VerismoTx]

Today, we share a significant company milestone. We received clearance for our IND from the FDA to initiate a first-in-human Ph1 trial of SynKIR-110. Read the release here: https://t.co/88inNgswpy #ovariancancer #cholangiocarcinoma #mesothelioma

[Verismo Therapeutics @VerismoTx]

We are excited to join @alliancerm. ARM and its members make help make meaningful changes in patients lives and we are honored to be a part of it. #cancer #regenerativemedicine #patientsfirst #synkir110

[Alliance for Regenerative Medicine (ARM) @alliancerm]

A warm welcome to our newest ARM members: @Apertura_GTX, C3i, Resolution Therapeutics, @caring_cross, Unicyte, @MinervaBio, @AviadoBio, @AssistanceFund, @capstantx, @Akadeum, @multiplylabs, @DimensionInx, @VerismoTx, and Laverock Therapeutics.

[Penn Innovation @PennPCI]

Penn spinout company Verismo Therapeutics announced that it has submitted an Investigational New Drug application to the FDA requesting approval to initiate its first-in-human Phase 1 clinical trial of its KIR-CAR T-cell immunotherapy drug SynKIR-110.

https://t.co/S5SiL1m13o

[Verismo Therapeutics @VerismoTx]

We are grateful to play a role in helping patients with a #RareDisease. Our #STAR101 trial testing our #SynKIR110 #KIRCAR will open in the 1st quarter of 2023 if approved by the #FDA.

[Rare Disease Advisor @RareDisease_Adv]

@VerismoTx  has submitted a #InvestigationalNewDrug application to the @US_FDA  to test its experimental treatment #SynKIR110 in patients with #Cholangiocarcinoma, among other diseases, in a first-in-human phase 1 #ClinicalTrial called #STAR101 https://t.co/qgrPc1NbrF #OncTwitter

[Verismo Therapeutics @VerismoTx]

We have submitted an IND for the first in-human trial of SynKIR-110, a KIR-CAR T cell Immunotherapy. Thank you to our focused and committed team for bringing us closer to helping patients with unmet medical needs. Full release: https://t.co/I2hM1dtZ3I
 #celltherapy #VerismoTx